Research Article

In Vivo Molecular Imaging of the Efficacy of Aminopeptidase N (APN/CD13) Receptor Inhibitor Treatment on Experimental Tumors Using 68Ga-NODAGA-c(NGR) Peptide

Figure 1

In vivo assessment of 68Ga-NODAGA-c(NGR) uptake of control-untreated and actinonin- and bestatin-treated HT1080 tumors. (a) Representative coronal decay-corrected PET images of control-untreated, bestatin-treated, and actinonin-treated tumor-bearing mice 5 (upper row) and 10 days (lower row) after tumor cell inoculation, and 90 min after intravenous injection of 68Ga-NODAGA-c(NGR). Red arrows: HT1080 tumor. (b) Quantitative decay-corrected SUV data analysis of 68Ga-NODAGA-c(NGR) uptake of treated and untreated HT1080 tumors 90 min after radiotracer injection. (c) Quantitative tumor-to-muscle ratio (T/M) analysis of treated and untreated HT1080 tumors 90 min after intravenous injection of 68Ga-NODAGA-c(NGR). SUVmean: standardized uptake value (mean). Significance levels: and . Data is presented as .
(a)
(b)
(c)